Browse studies

Find your next paid study

4 recruiting studies matching your filters

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAGChronosFP) in Patients With Geographic Atrophy Secondary to Dry AMD

This is a Phase 1/2 study, multi-center, dose-escalation interventional study of BS01 in subjects with GA secondary to dry AMD. Part 1 is an open label dose-es…

Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Bionic Sight LLCNCT07158775

Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration in Ophthalmology and Primary Care Settings

The purpose of this study is to perform a pivotal trial of iPredict, an automated AI-based system for early diagnosis and prediction of late AMD in primary car…

Age-related Macular Degeneration (AMD)

Estimated

~$10 – $1,050

Actual pay is set by the research site.

iHealthScreen IncNCT07084883

Optical Coherence Tomography Angiography in Neovascular Age-related Macular Degeneration

The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: 1. diagnose the presence of new blood ves…

Neovascular (Wet) Age-related Macular Degeneration (AMD)

Estimated

~$10 – $750

Actual pay is set by the research site.

Oregon Health and Science UniversityNCT02253030

Phase 3

A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) cau…

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Regeneron PharmaceuticalsNCT06541704